TP53 and cancer: Additionally, CTNNB1 and TP53 mutations were identified in single cases (0.8%) among the 125 individuals without malignant or premalignant diseases but were found in eight (20.5%) and five (12.8%), respectively, among the 39 women with endometrial malignancy, exhibiting that the frequencies are more than 16-fold higher in women with endometrial malignancy than those without malignancy.